Ayelen Toro ORCID: 0000-0002-5169-2006

Sofia Lage-Vickers ORCID: 0000-0001-8331-6331

Pin-pointing the key hubs in the IFN-y pathway responding to SARS-CoV-2 infection

Ayelen Toro^{1,2,*#}, Sofia Lage-Vickers^{1,2*#}, Juan Bizzotto^{1,2}, Felipe Vilicich¹, Agustina Sabater^{1,2,3}, Gaston Pascual^{1,2}, Sabrina Ledesma-Bazan^{1,2}, Pablo Sanchis^{1,2}, Maria S. Ruiz^{1,2}, Ana P. Arevalo⁴, Jorge L. Porfido⁴, Rocio Seniuk^{1,2}, Estefania Labanca⁵, Nicolas Anselmino⁵, Nora Navone⁵, Daniel F. Alonso⁶, Elba Vazquez^{1,2}, Martina Crispo⁴, Javier Cotignola^{1,2}, Geraldine Gueron^{1,2,*}

[#]Ayelen Toro and Sofia Lage-Vickers contributed equally and are co-first authors

*Corresponding authors: Geraldine Gueron, Ayelen Toro, Sofia Lage-Vickers

¹Laboratorio de Inflamación y Cáncer, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires C1428EGA, Argentina. <u>ggueron@iquibicen.fcen.uba.ar</u>

²CONICET-Universidad de Buenos Aires, Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN), Buenos Aires C1428EGA, Argentina

³Universidad Argentina de la Empresa (UADE), Instituto de Tecnología (INTEC), Buenos Aires C1073AAO, Argentina

⁴Laboratory Animals Biotechnology Unit, Institut Pasteur de Montevideo, Uruguay

⁵Department of Genitourinary Medical Oncology and The David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

⁶Centro de Oncología Molecular y Traslacional y Plataforma de Servicios Biotecnológicos, Departamento de Ciencia y Tecnología, Universidad Nacional de Quilmes, Bernal B1876BXD, Argentina

ABSTRACT

Interferon gamma may be a potential adjuvant immunotherapy for COVID-19 patients. In this work, we assessed gene expression profiles associated with the IFN-y pathway in response to SARS-CoV-2 infection. Employing a case-control study from SARS-CoV-2 positive and negative patients, we identified IFN-y-associated pathways to be enriched in positive patients. Bioinformatics analyses showed upregulation of MAP2K6, CBL, RUNX3, STAT1 and JAK2 in COVID-19 positive vs. negative patients. A positive correlation was observed between STAT1/JAK2, which varied alongside the patient's viral load. Expression of MX1, MX2, ISG15 and OAS1 (4 well-known IFN-stimulated genes (ISGs)) displayed upregulation in COVID-19 positive vs. negative patients. Integrative analyses showcased higher levels of ISGs which were associated with increased viral load and STAT1/JAK2 expression. Confirmation of ISGs up-regulation was performed in vitro using the A549 lung cell line treated with Poly(I:C), a synthetic analog of viral double-stranded RNA; and in different pulmonary human cell lines and ferret tracheal biopsies infected with SARS-CoV-2. A preclinical murine model of coronavirus infection confirmed findings displaying increased ISGs in the liver and lungs from infected mice. Altogether, these results demonstrate the role of IFN-γ and ISGs in response to SARS-CoV-2 infection, highlighting alternative druggable targets that can boost the host response.

KEY WORDS

IFN-γ, ISGs, COVID-19

INTRODUCTION

Coronaviruses are a family of viruses that can cause several illnesses, such as the common cold, the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS). Since 2002 there have been 3 different outbreaks caused by coronaviruses: in 2002 there was a SARS-CoV epidemic; in 2012 there was a MERS-CoV outbreak; and in 2020 the novel Coronavirus SARS-CoV-2 became a pandemic, being the third Coronavirus outbreak to emerge in the human population (1).

Interferons (IFNs) are the most important innate antiviral cytokines. Type I and type III IFNs (IFN-I and IFN-III, respectively) are expressed by most cell types and have the ability to induce an antiviral response within infected and surrounding cells (2). IFN-y, the type II IFN (IFN-II), is predominantly produced by immune cells. However, the IFN-γ receptor (IFNGR), which is composed of two subunits (IFNGR1 and IFNGR2), is ubiquitously expressed. Therefore, all cell types are capable of responding to IFN-y signals. Binding of IFN-y to the IFNGR1/2 results in the activation of the Janus Kinases 1 & 2 (JAK1 and JAK2), leading to the phosphorylation and homodimerization of the Signal Transducer and Activator of Transcription 1 (STAT1)(3). STAT1 dimers, also known as the gamma interferon-activated factor (GAF), translocate to the nucleus and promote gene expression by binding to the gamma interferon-activated site (GAS) of IFN-stimulated genes (ISGs) (4). In addition, after IFNGR stimulation, STAT1 is able to interact with other proteins such as STAT2 and Interferon Related Factor 9 (IRF9) which, in turn, regulate IFN-y-responsive genes by binding to the interferon stimulated response elements (ISRE) (4). Consequently, IFN exposure triggers the induction of more than 300 ISGs, such as the Myxovirus resistance genes 1 & 2 (MX1 and MX2), 2',5'-oligoadenylate synthetase 1 (OAS1), and Interferonstimulated gene 15 (ISG15), that collectively promote an antiviral response (5,6).

There are several studies that highlight IFNs as key players in COVID-19, and propose that a dysregulated IFN signaling pathway is associated with a poor prognosis (7–9). SARS-CoV-

2 has evolved several strategies to counteract not only IFN production, but also IFNsignaling. In fact, 16 viral proteins target the host's IFN-pathway at many levels to escape IFN-mediated restriction (10). Although much attention has been placed in the SARS-CoV-2mediated evasion of the IFN response, little is known about IFN-γ-associated genes and their role in COVID-19.

In this work, we undertook an extensive bioinformatics analysis in human patients positive or negative for SARS-CoV-2 to evaluate gene expression profiles associated with the canonical and non-canonical IFN-γ pathways. Validation of results were performed *in vitro* and *in vivo* in ferrets and in a murine coronavirus model of infection. Our results evidence the involvement of the IFN-γ signaling pathway in COVID-19, pointing out to a potential mechanism involved in SARS-CoV-2 infection, highlighting alternative druggable targets that can boost the host response against SARS-CoV-2.

MATERIALS AND METHODS

Transcriptome datasets selection

To identify potential relevant studies with transcriptome data related to SARS-CoV-2 infection and COVID-19 patients we browsed the following databases: Gene Expression Omnibus (GEO) repository (11), Genotype-Tissue Expression (GTEx) project (12), Genome Sequence Archive (GSA) on the National Genomics Data Center (13), PubMed (14), and Google Scholar (15). We used the following keywords and expressions: [(COVID) OR (COVID-19) OR (CORONAVIRUS) OR (SARS-CoV-2) OR (2019-nCoV)] AND [(transcriptomics) OR (RNA-seq) OR (microarray) OR (expression) OR (transcriptome)].

All potentially relevant datasets were further evaluated in detail by 2-3 authors. The eligibility criteria included: (i) publicly available transcriptome data (gene expression microarray, RNA-seq); (ii) detailed sample information; (iii) detailed protocol information. We selected the following datasets that complied with these criteria:

- GSE147507 (16): RNA-seq data from: (i) human cell lines derived from primary bronchial/tracheal epithelial cells (NHBE), lung carcinoma (A549) and lung adenocarcinoma (Calu-3) infected with SARS-CoV-2 (MOIs: 2, 0.2 and 2, respectively) or mock-PBS; and (ii) tracheal samples from ferrets intranasally infected with 5×10⁴ PFU of SARS-CoV-2 or mock-PBS.
- GSE152075 (17): RNA-seq data from 430 SARS-CoV-2 positive and 54 negative patients. Clinico-pathological information included age, sex, and viral load. The cycle threshold (Ct) by RT-qPCR for the N1 viral gene at time of diagnosis was used to determine the viral load. The interpretation for viral load was: the higher the viral load, the lower the Ct.
- GSE32138 (18): Whole Human Genome Microarray from human airway epithelial cells from non-cystic fibrosis patients resected at lung transplantation. Cells were infected with Influenza A Virus (IAV, 2×10⁵ PFU) or Respiratory Syncytial Virus (RSV, 1×10⁶ PFU) or mock, and harvested 24 h or 48 h post infection, respectively.
- GSE100504 (19): Whole Human Genome Microarray from human airway epithelium cultures. Cells were infected with wild type MERS-CoV (MOI 5) or mock for 48 h.
- GSE47963 (20): Whole Human Genome Microarray from human airway epithelium cultures. Cells were infected with wild type SARS-CoV (MOI 2) or mock for 48 h.

Bioinformatics analyses

RNA-seq analysis

We downloaded the raw RNA-seq data and checked the quality of reads by FastQC software (Institute). Sequences were aligned to the reference genome GRCh38 using STAR aligner (21), normalized by transcript length and GC content using the hg38 genome

annotation with metaseqR package in R (22). Additionally, within and between lanes normalization was performed using the EDAseq package in R (23).

The comparisons were plotted using pheatmap (24), ggplot2 (25) and ggpubr (26) packages in R. 3D plots were done using matplotlib.pyplot package in Python. Student's t test was performed to determine statistical differences.

Microarray analysis

We downloaded the normalized gene expression data from all microarrays datasets. The comparisons were plotted using pheatmap (24), ggplot2 (25) and ggpubr (26) packages in R. Student's t test was performed to determine statistical differences.

Gene Correlation

Pairwise gene correlation between the IFN- γ associated genes that were differentially expressed in COVID-19 positive vs. negative patients was analyzed with the ggcorrplot package in R. Correlation coefficients were classified as weak ($|r| \le 0.33$), intermediate (0.33 < |r| < 0.66), and strong ($|r| \ge 0.66$). Statistical significance was set at *p* < 0.05.

Profiling of immune cell type abundance from bulk gene expression data using CIBERSORT

CIBERSORT web tool (27) was used to estimate the abundances of immune cell types based on the LM22 signature on normalized bulk RNA-seq gene expression data. Results were displayed as heatmaps by non-supervised clustering on rows and columns using pheatmap function in R (24).

Gene Set Variation Analysis

Assessment of gene set enrichment was performed on normalized RNA-seq gene expression data using Gene Set Variation Analysis (GSVA) tool in R (28). GSVA uses a non-

parametric, unsupervised method that allows the estimation of the relative enrichment of pathways across samples. "C2:KEGG", "C2:REACTOME", "C5" and "C7" geneset collections were downloaded using *msigdbr* (29) package in R. Results were filtered and only genesets that include "interferon", "IFN", and "gamma" were used for subsequent analysis and visualization.

Cell culture conditions

Human lung carcinoma A549 (ATCC® CCL-185[™]) cells were grown in Dulbecco's modified Eagle's medium (DMEM, Gibco, Rockville, MD, USA) plus 10% fetal bovine serum (FBS) (Internegocios, Buenos Aires, Argentina), penicillin 100 U/ml, streptomycin 100 µg/ml, amphotericin 0.5 µg/ml, 2 mM glutamine, and 80 µg/ml gentamycin in a monolayer culture, at 37 °C in a humidified atmosphere of 5% CO₂. Cells were harvested using a trypsin/EDTA solution (Gibco) diluted in PBS and routinely tested for mycoplasma.

Poly (I:C) Treatment

Poly (I:C) intracellular administration was performed by transfection with Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions at a final concentration of Poly (I:C) of 10 μ g/ml. Briefly, A549 cells were plated in 6-well flat bottom plates at a density of 2×10⁵ cells in complete DMEM, allowed to attach overnight, and then transfected with Poly (I:C) or distilled water as mock in DMEM without FBS and antibiotics. After 6 h, the media were replaced and 24 h later total cell lysates and RNA isolation was carried out (30).

In vivo experiments

BALB/cJ female mice (n=10; 8-10 weeks old) were bred at the animal facility of the Laboratory Animals Biotechnology Unit of Institut Pasteur de Montevideo under specific pathogen-free conditions in individually ventilated racks (IVC, 1285L, Tecniplast, Milan, Italy). The housing environmental conditions during the experiment were as follows: 20 ± 1

°C temperature, 30–70% relative humidity, negative pressure (biocontainment) and a light/dark cycle of 14/10 h. All procedures were performed under Biosafety level II conditions. Mice were randomly distributed into two experimental groups: non-infected ($n \equiv = 5$) and infected ($n \equiv = 5$) groups. Mice were infected by intraperitoneal injection of 100 µl of MHV-A59 (6000 PFU) (ATCC VR-764) diluted in sterile PBS. Five days after intraperitoneal infection mice were weighed and euthanized by cervical dislocation to dissect the liver and lung for RT-qPCR analyses. The experimental protocols were approved by the institutional *Comisión de Ética en el Uso de Animales* (protocol #008-16) and were performed according to national law #18.611 and relevant international laboratory animal welfare guidelines and regulations.

RNA Isolation, c-DNA Synthesis, and Quantitative Real-Time PCR (RT-qPCR)

Total RNA was isolated with Quick-Zol (Kalium technologies, Buenos Aires, Argentina) according to the manufacturer's protocol. cDNAs were synthesized with TransScript One-Step gDNA Removal and cDNA Synthesis SuperMix (Transgen Biotec, Beijin, China) using random primers. Taq DNA Polymerase (Invitrogen, Waltham, MA, USA) was used for real-time PCR amplification in a QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA), using the primers listed in **Table 1**. *hPPIA and* m*Gapdh* were used as the internal reference genes. Data were analyzed using the method of 2^{-ΔΔCT} (31).

Quantification of viral load was performed as previously described (32), using the following primers for MHV detection.

Gene	Forward (5´- 3´)	Reverse (5´- 3´)	Annealing (°C)
h <i>MX1</i>	AGGACCATCGGAATCTTGAC	TCAGGTGGAACACGAGGTTC	60
h <i>MX</i> 2	GGCAGAGGCAACCAAGAAAGA	AACGGGAGCGATTTTTGGA	60
h/SG15	GTCCTGCTGGTGGTGGACAAA	GTCCTGCTGGTGGTGGACAAA	61

Table 1. List of pr	imers used in	RT-qPCR.
---------------------	---------------	----------

hOAS1	GGGATTTCGGACGGTCTTGG	TCTCCACCACCCAAGTTTCC	60
h <i>PPIA</i>	GGTATAAAAGGGGCGGGAGG	CTGCAAACAGCTCAAAGGAGAC	60
m <i>Mx1</i>	TGCCAGGACCAGGTTTACAAG	CCCCTTTTGAGGAAACTGAGA	58
m <i>Mx2</i>	CCTATTCACCAGGCTCCGAA	TCTCGTCCACGGTACTGCTT	58
m <i>lsg15</i>	TGAGAGCAAGCAGCCAGAAG	CCCCCAGCATCTTCACCTTT	57
m <i>Oas1</i>	ACTTCCTGAACTGTCGCCC	ACTCGACTCCCATACTCCCAG	61
m <i>Gapdh</i>	TGCCAAGGCTGTGGGCAAGG	CGAAGGTGGAAGAGTGGG	60
MHV	GGAACTTCTCGTTGGGCATTATACT	ACCACAAGATTATCATTTTCACAACATA	60

Statistical analyses

Wilcoxon rank sum test was performed to determine statistical differences between categorical groups. Age was categorized according to the WHO guidelines ("World Health Organization 2020 - Novel Coronavirus (2019-nCoV) Situation Report - 1," n.d.): <30 years old, every 10 years between 30-70 years old and \geq 70 years old. Two-sided, increasing and decreasing Jonckheere-Terpstra trend tests (with 500 permutations) were used to determine gene expression trends among age groups. To study pairwise correlations between continuous variables, Spearman's rank correlation coefficient was calculated. Multilinear regression analyses were performed to determine the correlation between the expression of two genes and viral load. To estimate the regression coefficients of the different models, we used a multivariable regression including gene expression, viral load and age as covariates. All statistical analyses were done in Stata v14 (StataCorp LLC, College Station, TX, USA) or GraphPad Prism (La Jolla, CA, USA). Statistical significance was set as $p \leq 0.05$. Principal Component Analysis (PCA) was done with the factor extra and dplyr packages in R (33).

RESULTS

Analysis of IFN-γ pathway in COVID-19 positive and negative patients

To study the relevance of the IFNs production and downstream signaling during SARS-CoV-2 infection, we used the publicly available RNA sequencing (RNA-seq) dataset GSE152075, which consists of transcriptomic data from nasopharyngeal swabs from 430 SARS-CoV-2

positive and 54 SARS-CoV-2 negative patients (**Figure 1A**). Patient demographics are available in **Supplementary Table S1**. To assess whether COVID-19 infection was associated with differential activation of the IFN pathways, we performed a gene set enrichment analysis (GSEA) among COVID-19 positive vs. COVID-19 negative patients. We decided to focus on IFN-γ related genes since the expressions of *IFNAR1*, *IFNAR2* and *IFNLR1* were comparable between COVID-19 positive and negative patients (**Supplementary Figure S1 i, ii & iii, respectively**). Information for *IFNA, IFNB* and *IFNL* was not available in this dataset. Regarding the IFN-γ pathway, results showed that both regulation and response to IFN-γ were differentially activated at the RNA level in COVID-19 positive patients (**Figure 1B**). Results showed that the degree of pathway activation was associated with viral load in COVID-19 positive patients, while non-COVID-19 patients presented the lowest GSVA scores (**Figure 1C & Supplementary Figure S2**).

We also evaluated whether activation of the IFN-γ pathway was associated with the immune response by estimation of immune cell type proportions from bulk gene expression data using the CIBERSORT tool. We performed an unsupervised clustering analysis, observing a group of patients with a higher proportion of M1 macrophages, enriched in patients with higher viral load (**Figure 1D**). Further, results showed a positive correlation between categories related to regulation and response to IFN-γ and the rate of M1 macrophages (**Figure 1E**).

Next, we performed an extensive bibliographic research to obtain a list of the IFN- γ associated genes and classified them into two categories: 1) genes belonging to the canonical pathway, and 2) genes belonging to the non-canonical pathways (34) (**Figure 2A & Supplementary Table S2, respectively**). First, we evaluated the expression of the six IFN- γ -canonical pathway genes (**Figure 2B**). Results showed a differential expression of 3 out of the 6 genes analyzed when comparing COVID-19 positive *vs.* negative patients: *IFNGR1* expression was decreased (p = 0.028) (**Figure 2B ii**), while *JAK2* and *STAT1* expressions were increased ($p \le 0.001$ for both genes) (**Figure 2B v & vi, respectively**). No

significant differences were observed for the rest of the genes. Next, we analyzed the expression of 26 IFN- γ -related genes included in the non-canonical pathways related to the immune response, cell proliferation and cell cycle regulation (**Figure 2A & Supplementary Table S2**). A decrease in the expression of the following genes was also observed in COVID-19 positive patients: *RAPGEF1* (p = 0.0091), *MAP2K1* (p = 0.038), *CEBPB* (p = 3.3e-06), *STAT6* (p = 0.041), *JUN* (p = 1.4e-08), *PRKACA* (p = 0.021), and *AKT1* (p = 1.3e-06) (**Supplementary Figure S3A**). Additionally, an increase in the expression of *MAP2K6*, *CBL* and *RUNX3* was observed in COVID-19 positive patients (p = 0.047; p = 0.0093; and p = 0.0044, respectively) (**Supplementary Figure S3A**).

Next, we evaluated whether gene expression might be associated with patients' sex and age, as COVID-19-associated risk factors. Although no significant differences were found when comparing gene expression based on patients' sex (Figure 2C i & Supplementary Figure S3B), the expressions for the following genes belonging to the IFN-y canonical pathway, decreased with age in COVID-19 positive patients: IFNG (p-trend_{decreasing} = 0.002), IFNGR2 (p-trend decreasing = 0.04), JAK1 (p-trend decreasing = 0.002), JAK2 (p-trend decreasing = 0.002) and STAT1 (p-trend decreasing = 0.002) (Figure 2C ii, right panel). Additionally, the expressions of STAT3 (p-trend decreasing = 0.01), RUNX3 (p-trend decreasing = 0.002), RAPGEF1 (p-trend decreasing = 0.004), RAP1A (p-trend decreasing = 0.004), RAC1 (p-trend decreasing = 0.002), PTK2B (p-trend decreasing = 0.01), MAPK1 (p-trend decreasing = 0.002), MAP3K1 (p-trend decreasing = 0.004), MAP2K6 (p-trend decreasing = 0.02), CPKL (p-trend decreasing = 0.004), CBL (p-trend decreasing = 0.002), AKT1 (p-trend decreasing = 0.008), and CREBBP (p-trend decreasing = 0.01) decreased with age (Supplementary Figure S3C ii). On the contrary, there was no association between gene expression and age in non-COVID-19 patients (Figure 2C ii, top panel & Supplementary Figure S3C i). Of note, both STAT1 and JAK2, whose expression is significantly increased during SARS-CoV-2 infection, decrease their expression in older patients (Figure 2C ii).

Gene correlation analysis of dysregulated IFN-γ associated genes in COVID-19 positive and negative patients

Further, in order to increase the interpretability of the data and to acquire a better understanding of the results obtained in the differential gene expression study, we performed a pairwise correlation analysis between the 13 genes that showed a differential expression between COVID-19 positive and negative patients (Figure 3A). Patients were segregated into 3 groups: all patients (group 1), non-COVID-19 patients (group 2), and COVID-19 patients (group 3). Results showed significant (p < 0.05) and intermediate (0.33 < |r| < 0.66) correlations among several IFN-y associated genes for COVID-19 positive patients: *MAP2K6/JAK2* (r = 0.569, *p* < 0.001); *CEBPB/JAK2* (r = 0.466, *p* < 0.001); *CEBPB/CEBL* (r = 0.457, *p* < 0.001); *CEBPB/RUNX3* (r = 0.440, *p* < 0.001); *JUN/JAK2* (r = 0.480, *p* < 0.001); JUN/STAT1 (r = 0.410, p < 0.001); JUN/CBL (r = 0.385, p < 0.001); JUN/RAPGEF1 (r = 0.495, p < 0.001; JUN/MAP2K6 (r = 0.346, p < 0.001); PRKACA/JAK2 (r = 0.419, p < 0.001); PRKACA/CBL (r = 0.518, p < 0.001); AKT1/JAK2 (r = 0.441, p < 0.001); AKT1/STAT1 (r = 0.510, p < 0.001) and AKT1/CBL (r = 0.525, p < 0.001), whereas correlations for the same pairs of genes in non-COVID-19 patients were non-significant (Figure 3A). Interestingly, although JAK2 and STAT1, two of the main genes involved in the IFN-y canonical pathway, presented a positive and significant correlation for non-COVID19 (r = 0.390, p < 0.01), this correlation was significantly increased in COVID-19 positive patients (r = 0.82, p < 0.001) patients (**Figure 3A**). Further, this correlation was associated with viral load (Figure 3B & C). These results suggest that STAT1 and JAK2 might be key responders to SARS-CoV-2 infection.

SARS-CoV-2 viral load association with IFN-y related genes and ISGs

Taking into account our previous results, we next analyzed the association between the expressions of *JAK2*, *STAT1* and 4 key IFN-inducible genes (ISGs) relevant in the antiviral response: *MX1*, *MX2*, *ISG15* and *OAS1* (**Figure 4A**). The expression of these ISGs was

higher in COVID-19 positive compared with COVID-19 negative patients (**Figure 4B**). Furthermore, results evidenced that COVID-19 positive patients with higher expressions of *JAK2* and *STAT1* showed increased *MX1, MX2, ISG15* and *OAS1* mRNA levels (**Figure 4C**). Since *MX1, MX2, ISG15* and *OAS1* showed a similar expression pattern in COVID-19 positive patients, we next evaluated the association of their combined expressions with viral load. Results showed that higher levels of these 4 ISGs are associated with a higher viral load (**Figure 4D**). Moreover, the combined expression of *MX1, MX2, ISG15* and *OAS1* showed a significant and positive correlation with the combined expression of *JAK2* and *STAT1* (**Figure 4E**).

Finally, we assessed the association between the combined expression of JAK2 + STAT1and MX1 + MX2 + ISG15 + OAS1 with viral load using a linear univariable regression analysis. Results evidenced that viral load is associated with an increase in the combined expression of JAK2 + STAT1 (p = 0.008) and MX1 + MX2 + ISG15 + OAS1 (p = 0.005) (**Figure 4F i**). Furthermore, when analyzing the individual expression of the selected genes, we observed that viral load can explain variations in JAK2 (p = 0.048), STAT1 (p = 0.007), MX1 (p < 0.001), ISG15 (p = 0.002) and OAS1 (p < 0.001). Non-significant differences were observed for MX2 association with viral load (p = 0.35) (**Figure 4F ii**). In conclusion, these results suggest that viral load influenced JAK2, STAT1, MX1, ISG15 and OAS1 expression, however, its effect is prominent in MX1 levels.

Targets of IFN-y pathway in response to viral infection

To further assess the alterations in *MX1*, *MX2*, *ISG15* and *OAS1* in response to viral infections and validate our results, we performed *in vitro* assays in A549 cells using Poly (I:C), a synthetic analog of viral double-stranded RNA, to mimic a viral infection (**Figure 5A i**). We found that *MX1*, *MX2*, *ISG15* and *OAS1* expressions were significantly increased in A549 cells treated with Poly (I:C) 10 μ M during 24 h (p < 0.05 for *MX1*, *MX2* and *OAS1*; and p < 0.001 for *ISG15*) (**Figure 5A ii**). Additionally, we evaluated the 4 ISGs response against

single stranded RNA viruses, such as Influenza A virus (IAV), Respiratory syncytial virus (RSV), Middle East respiratory Syndrome (MERS-CoV) and SARS-CoV-1 (Supplementary Figure S4). As expected, MX1, MX2, ISG15 and OAS1 were up-regulated in human airway epithelial cells (hAEC) infected with IAV (p < 0.001 for all genes), RSV (p < 0.001 for all genes), MERS-CoV (p < 0.001 for MX1, ISG15 and OAS1; and p < 0.01 for MX2) and SARS-CoV-1 (p < 0.001 for MX1 and ISG15; and p < 0.01 for MX2) compared with mock treatment; confirming MX1, MX2, ISG15 and OAS1 overexpression during different viral infections (Supplementary Figure S4). We next assessed MX1, MX2, ISG15 and OAS1 expression levels in response to SARS-CoV-2 infection (Figure 5B & C). We used the GSE147507 dataset which contains RNA-seq expression data from lung cell lines (A549, Calu-3 and NHBE), as well as tracheal biopsies of SARS-CoV-2 infected ferrets. Results showed that MX1, MX2 and OAS1 were over-expressed in SARS-CoV-2 infected A549 cells (p < 0.01 for MX1, ISG15 and OAS1; and p < 0.05 for MX2), and Calu-3 cells (p < 0.05 for MX2)MX1, ISG15 and OAS1; and p < 0.01 for MX2) compared with mock infection (Figure 5B). In NHBE cells, only MX1, MX2 and OAS1 were significantly over-expressed in SARS-CoV-2 infected cells compared with mock infection (p < 0.05 for MX1 and OAS1; and p < 0.01 for MX2) (Figure 5B). Further, SARS-CoV-2 infection significantly induced these ISGs in ferret tracheal biopsy samples collected at day 3 after infection compared with mock-treated animals (p < 0.01 for MX1; and p < 0.05 for MX2, ISG15 and OAS1) (Figure 5C). Altogether, these results confirm that the expression of MX1, MX2, ISG15 and OAS1 was triggered by SARS-CoV-2 infection.

Finally, we validated our results by studying the expression of *Mx1*, *Mx2*, *Isg15* and *Oas1* in a murine model of Coronavirus infection using the mouse hepatitis virus (MHV), a type 2 family RNA Coronavirus similar to SARS-CoV-2. We selected this model as an alternative pre-clinical model for the study of Coronavirus infection. BALB/cJ mice were infected with 6000 PFU of MHV-A59 by intraperitoneal injection and five days after infection liver and lung were dissected for RT-qPCR analyses (**Figure 6A**). First, we confirmed that the infection

was successful by qPCR analysis of the viral load. Results showed that viral infection was detectable in the liver and lungs, the main organs affected by MHV (**Figure 6B i & ii**). We next evaluated the expression of *Mx1*, *Mx2*, *Isg15* and *Oas1* in non-infected vs. infected mice, and found that all 4 genes were increased in the liver (p < 0.01 for *Mx1* and *Isg15*; and p < 0.05 for *Mx2* and *Oas1*) and lungs (p < 0.01 for *Mx1*, *Mx2* and *Isg15*; and p < 0.05 for *Mx2* and *Oas1*) and lungs (p < 0.01 for *Mx1*, *Mx2* and *Isg15*; and p < 0.05 for *Oas1*) of infected mice (**Figure 6C**). Our results validate the relevance of these 4 ISGs against Coronavirus infection.

CONCLUSIONS

The aim of the present work was to assess the implication of the of IFN- γ pathway in response to SARS-CoV-2 infection. Results from an extensive bioinformatics analyses in a case-control study from COVID-19 positive (n = 430) and negative (n = 54) patients, identified a signature of 13 dysregulated IFN- γ -associated genes including *STAT1* and *JAK2*, both key mediators of the IFN- γ signaling. *STAT1/JAK2* positively correlated with *MX1*, *MX2*, *ISG15* and *OAS1*, four well-known genes regulated by IFN (6). Further, higher levels of these ISGs combined showed a significant association with the viral load. We validated the relevance of *MX1*, *MX2*, *ISG15* and *OAS1* in the context of viral infections in cell cultures *in vitro* and in a pre-clinical model of Coronavirus infection (35).

IFNs are essential key players against viral infections through the induction of ISGs, that work in synergy to inhibit the replication and spread of the virus (36,37). However, IFNs show differential associations with clinical markers of poor prognosis and COVID-19 severity (38). Regarding IFN-I's role in COVID-19, it was demonstrated that numerous SARS-CoV-2 proteins have the ability to inhibit IFN-I production and/or IFN-I responses (39), producing resistance to this antiviral mechanism (40). Although viruses display strategies to evade the IFN antiviral activity, there are host-factors that affect the severity of the disease. For example, the generation of auto-antibodies that target IFN-I has the potential to affect the course of SARS-CoV-2 infection, suggesting that IFN deficiency may result in severe

COVID-19 (7,41). Further, an enrichment in loss-of-function variants in IFN-I pathway-related genes was reported in severe COVID-19 cases (8). In addition, Hadjadj et al. observed that peripheral blood immune cells from severe and critical COVID-19 patients have diminished IFN-I production and enhanced proinflammatory cytokines (42). Hence, severe COVID-19 patients might be potentially relieved from the IFN-I deficiency through IFN administration (42). Concerning the IFN-III association with COVID-19, reduced protein levels of IFN- λ were also correlated with a higher disease severity (9). However, there is scarce evidence linking the IFN-II pathway to COVID-19.

In this work, we evidenced the alteration of IFN-γ-associated genes during SARS-CoV-2 infection. Our results rendered 13 dysregulated genes when comparing COVID-19 positive vs, negative patients, suggesting an IFN-y-related gene expression signature characteristic of COVID-19 disease. Comparatively, Galbraith et al. performed a multi-omics investigation of systemic IFN signaling in hospitalized SARS-CoV-2 infected patients, with varying levels of IFNs (38). Of note, it has been reported that higher expression levels of IFN-y in the upper airway determine pathogenesis of COVID-19 (43), as it correlates with higher levels of ACE2, thus increasing susceptibility to infection (43). It has also been reported that IFN-ydriven inflammatory responses contribute to SARS-CoV-2 replication (44). Further, IFN-y contributes to COVID-19 complications, such as cytokine storm, tissue damage and inflammation (45), since an exacerbated immune response may also cause damage to the host. Previous reports evidenced that this cytokine is over-expressed in patients that died of COVID-19, when comparing its expression in patients who survived, highlighting it as a mortality risk factor (46). Alternatively, other studies reported that in critically ill COVID-19 patients IFN-y administration was followed by viral clearance and clinical improvement (47,48). Moreover, no information is available about the expression of IFN-γ downstream genes in this cohort of patients. Additionally, it has also been suggested that enhancing STAT1's activity might be an effective COVID-19 treatment (49), thus bypassing the adverse effects of IFN-based therapeutics.

The insights into the dysregulation of IFN pathways in COVID-19 patients provide biological basis for new therapies. Further, targeting IFN downstream genes might be advantageous considering the pleiotropic activities of human IFNs (50). Notably, in the present work we demonstrated that the expressions of the ISGs *MX1*, *MX2*, *ISG15* and *OAS1* were upregulated in COVID-19 positive vs. negative patients.

MX1 encodes a guanosine triphosphate (GTP)-metabolizing protein that inhibits the replication of RNA and DNA viruses in the nucleus, while *MX2* is a GTPase that has a reported potent antiviral activity in the cytoplasm (51). In a recent work from our group, we highlighted the relevance of *MX1* as an antiviral SARS-CoV-2 host effector (52). Here, we validated *MX1* and *MX2* relevance *in vitro* and in a valuable murine model of Coronavirus infection. Not much information is available concerning *MX1* and *MX2* during SARS-CoV-2 infection, however, in melanoma cell lines, it was reported that persistent IFN- γ stimulation increases the expression and genome occupancy of STAT1 and induces the expression of ISGs, such as *IFIT1* and *MX1* (53). A study of red blood cells' methylome demonstrated a hypomethylation of *MX1* in samples from COVID-19 hospitalized patients, highlighting the relevance of the INF- γ pathway modulation during SARS-CoV-2 infection (54).

ISG15 encodes an ubiquitin-like protein that interacts with viral proteins during an infection, resulting in their loss of function (55,56). Further, free extracellular ISG15 acts as an amplifier of inflammation, exacerbating production of cytokines by macrophages (57). Regarding the mechanisms that the SARS-CoV-2 employs in order to evade the antiviral immune response, it has been reported that the viral papain-like protease (PLpro) acts as a deISGylation enzyme that cleaves ISG15 from its substrates, contributing to the evasion of the host immune system (58).

OAS1 participates in the innate cellular antiviral response. This enzyme synthesizes oligomers that activate RNAse L, which degrades cellular and viral RNA and impairs viral replication (59). Danziger et al., found that OAS1 catalytic activity is required for antiviral

response against SARS-CoV-2 (60). Moreover, a membrane-associated OAS1 form could act as a ds-RNA sensor in infection sites. Further, *OAS* was identified as a COVID-19 risk locus in association studies suggesting that the splice-site variant at this locus may reduce the enzymatic activity of OAS-1 influencing COVID-19 outcomes (61,62). Furthermore, Hurguin et al. reported an over-expression of *OAS1*, *MX1* and *MX2* after IFN- γ induction of a HeLa-derived cell line (63), confirming that the IFN- γ signaling promotes the expression of our ISGs signature.

Taking into account the current public health emergency of international concern, it is essential to increase the development of alternative treatment options against COVID-19. Although much attention has been placed on virus host cell receptors, little has been explored on COVID-19 therapies targeting effector pathways and antiviral proteins (64). The main therapeutic avenues to halt respiratory virus infection consist of targeting the virus directly or targeting the host system. Even though the first strategy is highly efficient, it is limited by the sensitivity/resistance of the virus variants (65,66). Thus, deciphering the host response to viral infection, appears as critical. This study aimed at exploring the relevance of the IFN- γ signaling pathway during SARS-CoV-2 infection with the long-term goal of delineating new therapeutic targets for COVID-19. However, all the knowledge about the mechanisms that are triggered in the host cell as a consequence of the infection could also be applied to treat other viral infections (i.e., Dengue or Zika).

REFERENCES

- Meo SA, Alhowikan AM, Al-Khlaiwi T, Meo IM, Halepoto DM, Iqbal M, et al. Novel coronavirus 2019-nCoV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012–9.
- Stanifer ML, Guo C, Doldan P, Boulant S. Importance of Type I and III Interferons at Respiratory and Intestinal Barrier Surfaces. Front Immunol. 2020;11:608645.

- Lee AJ, Ashkar AA. The Dual Nature of Type I and Type II Interferons. Front Immunol. 2018;9:2061.
- Majoros A, Platanitis E, Kernbauer-Hölzl E, Rosebrock F, Müller M, Decker T. Canonical and Non-Canonical Aspects of JAK-STAT Signaling: Lessons from Interferons for Cytokine Responses. Front Immunol. 2017;8:29.
- García-Sastre A. Ten Strategies of Interferon Evasion by Viruses. Cell Host Microbe. 2017 Aug;22(2):176–84.
- Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513–45.
- Meffre E, Iwasaki A. Interferon deficiency can lead to severe COVID. Vol. 587, Nature. England; 2020. p. 374–6.
- Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. 2020 Oct;370(6515).
- Fukuda Y, Homma T, Inoue H, Onitsuka C, Ikeda H, Goto Y, et al. Downregulation of type III interferons in patients with severe COVID-19. J Med Virol. 2021 Jul;93(7):4559–63.
- Lee J-H, Koepke L, Kirchhoff F, Sparrer KMJ. Interferon antagonists encoded by SARS-CoV-2 at a glance. Med Microbiol Immunol. 2022 Apr;1–7.
- Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5.
- 12. Carithers LJ, Moore HM. The Genotype-Tissue Expression (GTEx) Project. Vol. 13,

Biopreservation and biobanking. 2015. p. 307-8.

- NGDC. National Genomics Data Center M, Partners Database Resources of the National Genomics Data Center in 2020. Nucleic Acids Res. 2020 Jan;48(D1):D24– 33.
- 14. PMC-Pubmed Central [Internet]. Available from: https://www.ncbi.nlm.nih.gov/pmc/
- 15. Google Scholar [Internet]. Available from: https://scholar.google.com/
- Blanco-Melo D, Nilsson-Payant BE, Liu W-C, Møller R, Panis M, Sachs D, et al. SARS-CoV-2 launches a unique transcriptional signature from in vitro, ex vivo, and in vivo systems. bioRxiv [Internet]. 2020; Available from: https://www.biorxiv.org/content/early/2020/03/24/2020.03.24.004655
- Lieberman NAP, Peddu V, Xie H, Shrestha L, Huang M-L, Mears MC, et al. In vivo antiviral host response to SARS-CoV-2 by viral load, sex, and age. bioRxiv Prepr Serv Biol [Internet]. 2020 Jun 22;2020.06.22.165225. Available from: https://pubmed.ncbi.nlm.nih.gov/32607510
- Ioannidis I, McNally B, Willette M, Peeples ME, Chaussabel D, Durbin JE, et al. Plasticity and virus specificity of the airway epithelial cell immune response during respiratory virus infection. J Virol. 2012 May;86(10):5422–36.
- Feng S, Heath E, Jefferson B, Joslyn C, Kvinge H, Mitchell HD, et al. Hypergraph models of biological networks to identify genes critical to pathogenic viral response. BMC Bioinformatics. 2021 May;22(1):287.
- Mitchell HD, Eisfeld AJ, Sims AC, McDermott JE, Matzke MM, Webb-Robertson B-JM, et al. A network integration approach to predict conserved regulators related to pathogenicity of influenza and SARS-CoV respiratory viruses. PLoS One. 2013;8(7):e69374.

- Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics [Internet]. 2012/10/25. 2013 Jan 1;29(1):15–21. Available from: https://pubmed.ncbi.nlm.nih.gov/23104886
- Moulos P, Hatzis P. Systematic integration of RNA-Seq statistical algorithms for accurate detection of differential gene expression patterns. Nucleic Acids Res. 2015 Feb;43(4):e25.
- Risso D, Schwartz K, Sherlock G, Dudoit S. GC-content normalization for RNA-Seq data. BMC Bioinformatics. 2011 Dec;12:480.
- Perry M. heatmaps: Flexible Heatmaps for Functional Genomics and Sequence Features [Internet]. 2020. Available from: https://rdrr.io/bioc/heatmaps/
- Wickham, Hadley. ggplot2. Elegant Graphics for Data Analysis. NY: Springer-Verlag;
 2016.
- Kassambara A. ggpubr: "ggplot2" Based Publication Ready Plots [Internet]. 2020.
 Available from: https://cran.r-project.org/web/packages/ggpubr/index.html
- Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol [Internet]. 2019;37(7):773–82. Available from: https://doi.org/10.1038/s41587-019-0114-2
- Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013 Jan;14:7.
- Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al.
 Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct;102(43):15545–50.

- Segatori VI, Garona J, Caligiuri LG, Bizzotto J, Lavignolle R, Toro A, et al. Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. Vol. 13, Viruses . 2021.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 Dec;25(4):402–8.
- Arévalo AP, Pagotto R, Pórfido JL, Daghero H, Segovia M, Yamasaki K, et al.
 Ivermectin reduces in vivo coronavirus infection in a mouse experimental model. Sci Rep. 2021 Mar;11(1):7132.
- 33. Kassambara A, Mundt F. factoextra: Extract and Visualize the Results of Multivariate Data Analyses. R package. [Internet]. 2020. Available from: https://cran.rproject.org/package=factoextra
- Tang M, Tian L, Luo G, Yu X. Interferon-Gamma-Mediated Osteoimmunology. Front Immunol. 2018;9:1508.
- Körner RW, Majjouti M, Alcazar MAA, Mahabir E. Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2.
 Viruses [Internet]. 2020 Aug 12;12(8):880. Available from: https://pubmed.ncbi.nlm.nih.gov/32806708
- Li S-F, Gong M-J, Zhao F-R, Shao J-J, Xie Y-L, Zhang Y-G, et al. Type I Interferons: Distinct Biological Activities and Current Applications for Viral Infection. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2018;51(5):2377–96.
- 37. Teijaro JR. Type I interferons in viral control and immune regulation. Curr Opin Virol.2016 Feb;16:31–40.

- Galbraith MD, Kinning KT, Sullivan KD, Araya P, Smith KP, Granrath RE, et al. Specialized interferon action in COVID-19. Proc Natl Acad Sci U S A. 2022 Mar;119(11).
- Palermo E, Di Carlo D, Sgarbanti M, Hiscott J. Type I Interferons in COVID-19 Pathogenesis. Vol. 10, Biology . 2021.
- Chen D-Y, Khan N, Close BJ, Goel RK, Blum B, Tavares AH, et al. SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway. J Virol. 2021 Sep;95(19):e0086221.
- 41. Fajgenbaum DC, Hayday AC, Rogers AJ, Towers GJ, Wack A, Zanoni I. Anti-type I interferon antibodies as a cause of severe COVID-19. Fac Rev. 2022;11:15.
- Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science [Internet]. 2020/07/13. 2020 Aug 7;369(6504):718–24. Available from: https://pubmed.ncbi.nlm.nih.gov/32661059
- 43. Montalvo Villalba MC, Valdés Ramírez O, Muné Jiménez M, Arencibia Garcia A,
 Martinez Alfonso J, González Baéz G, et al. Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients. Clin
 Immunol [Internet]. 2020;220:108576. Available from:
 https://www.sciencedirect.com/science/article/pii/S1521661620307361
- Heuberger J, Trimpert J, Vladimirova D, Goosmann C, Lin M, Schmuck R, et al.
 Epithelial response to IFN-γ promotes SARS-CoV-2 infection. EMBO Mol Med. 2021
 Apr;13(4):e13191.
- Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, et al.
 Synergism of TNF-α and IFN-γ Triggers Inflammatory Cell Death, Tissue Damage,

> and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. Cell [Internet]. 2021;184(1):149-168.e17. Available from: https://www.sciencedirect.com/science/article/pii/S0092867420315427

- 46. Gadotti AC, de Castro Deus M, Telles JP, Wind R, Goes M, Garcia Charello Ossoski R, et al. IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res [Internet]. 2020;289:198171. Available from: https://www.sciencedirect.com/science/article/pii/S0168170220310789
- 47. van Laarhoven A, Kurver L, Overheul GJ, Kooistra EJ, Abdo WF, van Crevel R, et al. Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: A case series. Med (New York, NY). 2021 Oct;2(10):1163-1170.e2.
- 48. Nguyen LS, Ait Hamou Z, Gastli N, Chapuis N, Pène F. Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis. Vol. 47, Intensive care medicine. 2021. p. 619–21.
- 49. Matsuyama T, Kubli SP, Yoshinaga SK, Pfeffer K, Mak TW. An aberrant STAT pathway is central to COVID-19. Cell Death Differ. 2020 Dec;27(12):3209–25.
- Garcia-Del-Barco D, Risco-Acevedo D, Berlanga-Acosta J, Martos-Benítez FD, Guillén-Nieto G. Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2. Front Immunol. 2021;12:655528.
- 51. Verhelst J, Hulpiau P, Saelens X. Mx proteins: antiviral gatekeepers that restrain the uninvited. Microbiol Mol Biol Rev. 2013 Dec;77(4):551–66.
- Bizzotto J, Sanchis P, Abbate M, Lage-Vickers S, Lavignolle R, Toro A, et al. SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients. iScience. 2020 Oct;23(10):101585.

- Visan I. The interferon signature. Nat Immunol [Internet]. 2017;18(2):151. Available from: https://doi.org/10.1038/ni.3670
- 54. Bińkowski J, Taryma-Leśniak O, Łuczkowska K, Niedzwiedź A, Lechowicz K, Strapagiel D, et al. Epigenetic activation of antiviral sensors and effectors of interferon response pathways during SARS-CoV-2 infection. Biomed Pharmacother [Internet].
 2022;113396. Available from: https://www.sciencedirect.com/science/article/pii/S0753332222007855
- Perng Y-C, Lenschow DJ. ISG15 in antiviral immunity and beyond. Nat Rev Microbiol [Internet]. 2018;16(7):423–39. Available from: https://doi.org/10.1038/s41579-018-0020-5
- 56. Zhao C, Collins MN, Hsiang T-Y, Krug RM. Interferon-induced ISG15 pathway: an ongoing virus-host battle. Trends Microbiol. 2013 Apr;21(4):181–6.
- Zhang M, Li J, Yan H, Huang J, Wang F, Liu T, et al. ISGylation in Innate Antiviral Immunity and Pathogen Defense Responses: A Review. Front cell Dev Biol. 2021;9:788410.
- Vere G, Alam MR, Farrar S, Kealy R, Kessler BM, O'Brien DP, et al. Targeting the Ubiquitylation and ISGylation Machinery for the Treatment of COVID-19.
 Biomolecules. 2022 Feb;12(2).
- 59. Schwartz SL, Park EN, Vachon VK, Danzy S, Lowen AC, Conn GL. Human OAS1 activation is highly dependent on both RNA sequence and context of activating RNA motifs. Nucleic Acids Res [Internet]. 2020 Jul 27;48(13):7520–31. Available from: https://doi.org/10.1093/nar/gkaa513
- 60. Danziger O, Patel RS, DeGrace EJ, Rosen MR, Rosenberg BR. Inducible CRISPR activation screen for interferon-stimulated genes identifies OAS1 as a SARS-CoV-2

restriction factor. PLoS Pathog. 2022 Apr;18(4):e1010464.

- 61. Huffman J, Butler-Laporte G, Khan A, Drivas TG, Peloso GM, Nakanishi T, et al. Alternative splicing of OAS1 alters the risk for severe COVID-19. medRxiv□: the preprint server for health sciences. 2021.
- Huffman JE, Butler-Laporte G, Khan A, Pairo-Castineira E, Drivas TG, Peloso GM, et al. Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. Nat Genet [Internet]. 2022;54(2):125–7. Available from: https://doi.org/10.1038/s41588-021-00996-8
- Hurgin V, Novick D, Werman A, Dinarello CA, Rubinstein M. Antiviral and immunoregulatory activities of IFN-gamma depend on constitutively expressed IL-1alpha. Proc Natl Acad Sci U S A. 2007 Mar;104(12):5044–9.
- 64. van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, et al. A guide to immunotherapy for COVID-19. Nat Med [Internet].
 2022;28(1):39–50. Available from: https://doi.org/10.1038/s41591-021-01643-9
- McKimm-Breschkin JL. Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance. Treat Respir Med. 2005;4(2):107–16.
- Monto AS. The role of antivirals in the control of influenza. Vaccine. 2003 May;21(16):1796–800.

FIGURE LEGENDS

TABLE 1. Table of employed primers, containing the gene name, sequences, and annealing temperature (T^o an.).

FIGURE 1. Global assessment at the transcriptional level of pathways and immune cell types related to IFN-y production, signaling and regulation of response in COVID-**19 positive and negative patients.** A) Experimental design of the GSE152075 dataset, composed of transcriptome data from nasopharyngeal swabs collected from 430 COVID-19 and 54 non-COVID-19 patients. B) Non-supervised clustering of patients according to their GSVA score in each geneset. Higher GSVA scores indicate higher activity of the geneset at the RNA level. Each column is labeled according to the COVID-19 viral load of each patient. COVID-19 patients with medium viral load were excluded from the analysis. C) Waterfall plots of selected genesets that were highly activated in COVID-19 patients vs. non-COVID-19 patients. Patients are ordered from the highest to the lowest GSVA score in each geneset. D) Unsupervised clustering of non-COVID-19 and COVID-19 patients according to the relative proportions of immune cell types estimated by CIBERSORT (LM22 signature) in RNA-seq data. Each column is labeled according to the COVID-19 viral load of each patient. COVID-19 patients with medium viral load were excluded from the analysis. E) Heatmap of Spearman correlation coefficients between each immune cell type estimated by CIBERSORT vs. GSVA scores. Only COVID-19 patients were included in the correlation analysis.

FIGURE 2. Expression of genes belonging to the canonical IFN-γ pathway in non-COVID-19 and COVID-19 patients. A) Schematic representation of IFN-γ signaling pathway associated genes. The canonical IFN-γ pathway is represented in green. B) Gene expression analysis (log_2 (norm counts +1)) for (i) *IFNG*, (ii) *IFNGR1*, (iii) *IFNGR2*, (iv) *JAK1*, (v) JAK2, and (vi) *STAT1* in COVID-19 (purple) vs. non-COVID-19 (pink) patients from the GSE152075 dataset, assessed by RNA-seq. *p*-values correspond to Wilcoxon rank-sum test. Black squares represent the median. C) Heatmaps depicting the fold change (high = pink; low = blue) for gene expression of genes belonging to the canonical IFN-γ pathway considering sex (i) and age groups 30s, 40s, 50s, 60s & 70s vs. <30 (ii) in non-COVID-19 (left panel) and COVID-19 (right panel) patients from the GSE152075 dataset, assessed by

RNA-seq. *p*-values correspond to decreasing Jonckheere-Terpstra trend test. Statistical significance *p < 0.05; **p < 0.01; ***p < 0.001.

FIGURE 3. Correlation analysis. A) Pairwise Spearman correlation matrix analysis between all genes of interest using the GSE152075 dataset. The upper half displays the Spearman coefficients (r) considering all patients (Corr; black), non-COVID-19 patients (Neg; pink), or COVID-19 patients (Pos; purple). Black boxes highlight pairs of genes that have significant correlation only in COVID-19 positive patients, except for JAK2/STAT1, that was the pair with the highest coefficient in COVID-19 positive patients. The lower half displays the scatterplots. B) Dot plot representing pairwise Spearman correlation for JAK2 and STAT1, considering viral load in COVID-19 positive patients from the GSE152075 dataset. Viral load is represented as a color scale and was categorized as Negative (pink), Low (first quartile; light blue), Intermediate (second and third quartile; purple) or High (fourth quartile; blue), and was considered as an independent variable expressed as cycle threshold (Ct) by RT-qPCR for the N1 viral gene at time of diagnosis. The interpretation for viral load is: the lower the Ct, the higher the viral load. C) Box plot representing the combined expression of JAK2 + STAT1 and their association with the viral load. Viral load was categorized as Negative (pink), Low (first quartile; light blue), Intermediate (second and third quartile; purple) or High (fourth quartile; blue). p-values correspond to Wilcoxon rank-sum test. Statistical significance *p < 0.05; **p < 0.01; ***p < 0.001.

FIGURE 4. Association between *STAT1*, *JAK1* and ISG's expressions using the GSE152075 dataset. A) Schematic representation of the canonical IFN- γ signaling pathway. B) Gene expression analysis (log₂ (norm counts +1)) for *MX1* (i), *MX2* (ii), *ISG15* (iii), and *OAS1* (iv) in COVID-19 (purple) vs. non-COVID-19 (pink) patients from the GSE152075 dataset, assessed by RNA-seq. *p*-values correspond to Wilcoxon rank-sum test. C) Dot plots representing the pairwise Spearman correlation between *STAT1* and *JAK1*, considering the expressions of *MX1* (ii), *MX2* (ii), *ISG15* (iii) and *OAS1* (iv) in COVID-19 positive patients. The independent variable is plotted in the x axis and the dependent variable is plotted in the y axis. *MX1*, *MX2*, *ISG15* and *OAS1* expressions are represented as a color scale (purple = high; pink = low). D) Box plot representing the combined expression of *MX1* + *MX2* + *ISG15* + *OAS1* and their association with the viral load. Viral load was categorized as Negative (pink), Low (first quartile; light blue), Intermediate (second and third quartile; purple) or High (fourth quartile; blue). *p*-values correspond to Wilcoxon rank-sum test. E) Dot plot representing pairwise Spearman correlation between *JAK2* + *STAT1* and *MX1* + *MX2* + *ISG15* + *OAS1* combined expressions, considering viral load in COVID-19 positive patients from the GSE152075 dataset. Viral load is represented as a color scale and was categorized as Negative (pink), Low (first quartile; light blue). Intermediate (second and third quartile; purple) or High (fourth quartile; blue). F) Forest plots representing the coefficient of the viral load as predictor variable in regression analyses (considering age and gender as covariables). (i) Model considering as response variable: combined expression of JAK2 + STAT1 or MX1 + MX2 + ISG15 + OAS1; and (ii) model considering response variable: individual expressions of JAK2, STAT1, MX1, MX2, ISG15 and OAS1. Coef.: Coefficient. CI: Confidence interval. Statistical significance *p < 0.05; **p < 0.01; ***p < 0.001.

FIGURE 5. Analysis of ISGs expression in viral infections. A) A549 cells were treated with Poly (I:C) for 24 h, and RNA was extracted for RT-qPCR analysis. (i) Schematic representation of the experimental design. (ii) *MX1*, *MX2*, *ISG15* and *OAS1* expressions assessed by RT-qPCR in A549 cells treated (purple) or not (pink) with Poly (I:C) (10 μ g/ml; 24 h). Values were relativized using *PPIA* as a reference gene and normalized to the control. B) *MX1*, *MX2*, *ISG15* and *OAS1* expressions in SARS-CoV-2 treated cells. (i) Schematic representation of the experimental design. (ii) *MX1*, *MX2*, *ISG15* and *OAS1* expressions in SARS-CoV-2 infected A549 (n = 6), Calu3 (n = 6) and NHBE (n = 10) cell lines (purple) (MOIs: 0.2, 2 and 2, respectively for 48 h) compared with mock (pink), assessed by RNA-seq, using the GSE147507 dataset. C) *MX1*, *MX2*, *ISG15* and *OAS1* expressions in SARS-CoV-2 treated ferrets. (i) Schematic representation of the experimental design. (ii) *MX1*, *MX2*, *ISG15* and *OAS1* expressions in SARS-CoV-2 treated ferrets. (i) Schematic representation of the experimental design. (ii) *MX1*, *MX2*, *ISG15* and *OAS1* expressions in SARS-CoV-2 treated ferrets. (i) Schematic representation of the experimental design. (ii) *MX1*, *MX2*, *ISG15* and *OAS1* expressions in SARS-CoV-2 treated ferrets. (i) Schematic representation of the experimental design. (ii) *MX1*, *MX2*, *ISG15* and *OAS1* expressions in SARS-CoV-2 infected ferrets. (i) Schematic representation of the experimental design. (ii) *MX1*, *MX2*, *ISG15* and *OAS1* expressions in SARS-CoV-2 infected (5×10⁴ PFU) (purple) vs.

mock-treated (pink) ferrets, assessed by RNA-seq in tracheal biopsy samples (n = 7), using the GSE147507 dataset. Samples were collected on day 3 after SARS-CoV-2 infection. Student's t test was performed to determine statistical differences. Statistical significance *p< 0.05; **p < 0.01; ***p < 0.001. ns: not significant.

FIGURE 6. Analysis of ISGs expression in a pre-clinical model of Coronavirus infection. A) Schematic representation of the experimental design. BALB/cJ female mice (n=10) were used for the *in vivo* experiments. Mice were randomly distributed into two experimental groups: non-infected (n \equiv =5) and infected (n \equiv =5) groups. Mice were infected with 6,000 PFU of MHV-A59 by intraperitoneal injection of 100 µl of the virus diluted in sterile PBS. Five days after infection, mice were weighed and euthanized by cervical dislocation to dissect the liver and lung for RT-qPCR analyses. B) Viral load was assessed by RT-qPCR in livers (i) and lungs (ii) of BALB/cJ mice infected (purple) or not (pink) with MHV-A59. Viral load is expressed as - cycle threshold (-Ct) by RT-qPCR for MHV. C) *Mx1* (i), *Mx2* (ii), *Isg15* (iii) and *Oas1* (iv) expressions assessed by RT-qPCR in livers and lungs of BALB/cJ mice infected (purple) or not (pink) with MHV-A59. Values were relativized using *Gapdh* as a reference gene and normalized to the control. Student's t test was performed to determine statistical differences. Statistical significance **p* < 0.05; ***p* < 0.01; ****p* < 0.001.

DATA AVAILABILITY STATEMENT: The data are available upon reasonable request.

ETHICS STATEMENT: The *in vivo* protocols were approved by the institutional *Comisión de Ética en el Uso de Animales* (protocol #008-16) and were performed according to national law #18.611 and relevant international laboratory animal welfare guidelines and regulations.

ACKNOWLEGEMENTS: This research was funded by the Agencia Nacional de Promocion de la Investigacion, el Desarrollo Tecnologico y la Innovación (ANPCyT), Argentina: PICT 2019-03215 CONICET.

CONFLICT OF INTEREST: The authors declare no conflict of interest.

PATIENT CONSENT STATEMENT: Not applicable.

PERMISSION TO REPRODUCE MATERIAL FROM OTHER SOURCES: Not applicable.

CLINICAL TRIAL REGISTRATION: Not applicable.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Áll rights reserved. No reuse allowed without permission.

FIGURE 1

-0.5

-1.0



GOBP_INTERFERON_GAMMA_PRODUCTION GOBP_INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY GOBP_CELLULAR_RESPONSE_TO_INTERFERON_GAMMA



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

FIGURE 2







A

В





(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

FIGURE 3

JAK2	STAT1	MAP2K6	CBL	RAPGEF1	MAP2K1	RUNX3	IFNGR1	CEBPB	STAT6	JUN	PRKACA	AKT1
0.2 -	Corr: 0.787***	Corr: 0.533***	Corr: 0.652***	Corr: 0.563***	Corr. 0.502***	Corr: 0.512***	Corr: 0.200***	Corr: 0.391***	Corr. 0.530***	Corr: 0.356***	Corr: 0.362***	Corr: 0.344***
0.1-	Neg.: 0.390** Pos.: 0.831***	Neg : 0.113 Pos.: 0.569***	Neg : 0.468*** Pos.: 0.657***	Neg : 0.299* Pos : 0.623***	Neg : 0.256* Pos : 0.554***	Neg: 0.338* Pos: 0.517***	Neg : 0.414** Pos : 0.203***	Neg.: 0.162 Pos.: 0.466***	Neg : 0.357* Pos.: 0.581***	Neg : 0.090 Pos : 0.480***	Neg.: 0.090 Pos.: 0.419***	Neg.: 0.006 Pos.: 0.441***
10.0 -	\sim	Corr: 0.579***	Corr: 0.741***	Corr: 0.613***	Corr: 0.496***	Corr: 0.587***	Corr: 0.144**	Corr: 0.368***	Corr: 0.520***	Corr: 0.269***	Corr: 0.414***	Corr: 0.385***
7.5 - 5.0 -	1	Neg.: 0.570*** Pos.: 0.589***	Pos.: 0.741***	Neg = 0.728*** Pos.: 0.678***	Neg.: 0.406** Pos.: 0.579***	Neg.: 0.565*** Pos.: 0.587***	Neg.: 0.191 Pos.: 0.177***	Neg. 0.331* Pos.: 0.470***	Neg.: 0.592*** Pos.: 0.570***	Neg0.058 Pos.: 0.410***	Neg. 0.319* Pos.: 0.482***	Neg_ 0.265. Pos.: 0.510***
12 -			Corr: 0.597***	Corr. 0.509***	Corr: 0.421***	Corr: 0.415***	Corr: 0.165***	Corr: 0.365***	Corr. 0.437***	Corr: 0.270***	Corr: 0.426***	Corr: 0.296***
4-	A.6	2	Neg.: 0.560*** Pos.: 0.593***	Neg.: 0.538*** Pos.: 0.523***	Neg.: 0.657*** Pos.: 0.416***	Neg.: 0.476*** Pos.: 0.397***	Neg.: 0.108 Pos.: 0.189***	Neg.: 0.343* Pos.: 0.410***	Neg.: 0.487*** Pos.: 0.446***	Neg.: 0.013 Pos.: 0.346***	Neg.: 0.384** Pos.; 0.452***	Neg.: 0.362** Pos.: 0.335***
0 - 10.0 - 7.5 -		AL ANTINA A		Corr: 0.681***	Corr: 0.553***	Corr: 0.655***	Corr: 0.214***	Corr: 0.378***	Corr: 0.552***	Corr: 0.260***	Corr; 0.449***	Corr: 0.426***
5.0 - 2.5 -	3 . A	6.15 1		Nag : 0.635*** Pos.: 0.726***	Neg.: 0.467*** Pos.: 0.600***	Neg.: 0.559*** Pos.: 0.654***	Neg.: 0.226 Pos.: 0.232***	Neg : 0.217 Pos.: 0.457***	Nog.: 0.527*** Pos.: 0.586***	Nog.: -0.197 Pos.: 0.385***	Neg : 0.155 Pos.: 0.518***	Nog : 0.220 Pos.: 0.525***
10.0 -				\sim	Corr. 0.553***	Corr: 0.616***	Corr: 0.237***	Corr: 0.567***	Corr: 0.637***	Corr: 0.467***	Corr: 0.555***	Corr: 0.642***
5.0 - 2.5 -	100				Neg:: 0.505*** Pos:: 0.551***	Nog:: 0.513*** Pos:: 0.658***	Neg:: 0.330" Pos:: 0.215""	Neg.: 0.497*** Pos.: 0.570***	Nog.: 0.671*** Pos.: 0.630***	Nog : 0.125 Pos : 0.495***	Nog.: 0.418** Pos.: 0.560***	Neg.: 0.492*** Pos.: 0.659***
£ 8-		A TAPANA A A			~	Corr: 0.428***	Corr: 0.316***	Corr: 0.393***	Corr: 0.436***	Corr: 0.393***	Corr: 0.412***	Corr: 0.385***
stur 2-				1		Neg.: 0.616***	Neg.: 0.361*	Neg.: 0.439**	Neg.: 0.560***	Neg.: 0.298*	Neg.: 0,569***	Neg.: 0.501***
0-444					_	~	Corr. 0 108*	Corr 0.371***	Corr 0 507***	Corr. 0.220***	Cor: 0.413***	Corr: 0.436***
LU 1.5 -	1. 1. C.	100	and the	100	100	\leq		Neg : 0.139		Neg0.035		
6 0.0 - A A A A A A A A A A A A A A A A A A		ALCONT A.A.	1000	1944 1960 E	1	_	Pos.: 0.100*	Pos.: 0.440***	Pos.: 0.530***	Pos.: 0.300***	Pos.: 0.443***	Pos.: 0.505***
6 - 4 -		10 24	1. 1. 1. 1. 1.	1 2000	Constant Sec.	ALCONT	1-	Neg.: 0.413**	Neg.: 0.428**	Neg. 0.450**	Neg 0.234	Neg. 0.234
2-	No. And	T- Milling	A State of the second s	All a state	No	A starting	~	Pos.: 0.227***	Pos.: 0.326***	Pos.: 0.273***	Pos.: 0.207***	Pos.: 0.239***
7.5 - 5.0 -	A STATEMENT	1.00		A LANGE	A	A Allanda	A CONTRACT		Corr: 0.541*** Neg : 0.561***	Corr: 0.504*** Neg : 0.563***	Corr: 0.477*** Neg.: 0.663***	Corr: 0.553*** Neg.: 0.613***
2.5 - 0.0 -	57 J-5	1	1997. J.A.	E. 3	Low - 30	Car Setar	heart		Pos.: 0.539***	Pos.: 0.456***	Pos.: 0.446***	Pos.: 0.522***
10.0 - 7.5 - 6.0 - 6.0	and the second	general and	1 ALL DANSE	1	Lands !!	i i nandela i	A START	A share and		Corr: 0.467***	Corr: 0.551***	Corr; 0.632***
2.5 -	Sec. A.	E. A.	6	C	E and the	Erente	A. S. A.	6.18	2	Pos.: 0.465***	Pos.: 0.543***	Pos.: 0.623***
9 - 6 -	· Carteres	a specific a	-	A	a prost	Par a later ."	1 . A Chi antes	a martinet	1	S	Corr: 0.368***	Corr: 0.408***
3 - 0 -		1 . A.	17	12 20	17 - A.	1	REVEN	2	<i>е</i> .,		Pos.: 0.326***	Pos.: 0.349***
6-2	and the second	125 24	1.00	1 10 (100-1	1 30005	1. secondar"	A CALCULARY	1.2.42	1 August 19	Landate ?-	. ^	Corr: 0.580***
2 - 0 -	Var and	5.5	A	Sec. Al		See. Still	Bernard		(in	Se	~ /	Pos.: 0.552***
7.5 -	and the second second	1	a successive		A shares	A State State	A State State	Sector As	A LANDAR	Burnet States	A share to	
2.5 -		4. 4	Mar and	1		Low The	No.	1	5			26
0.0 2.5 5.0 7.5	5.0 7.5 10.0	0 4 8 12	0.0 2.5 5.0 7.5 10	.00.0 2.5 5.0 7.5 10.0	0 0 2 4 6 8	0.0 2.5 5.0 7.5 log, (norm counts +	0 2 4 6 1	8 0.0 2.5 5.0 7.5 10.	00.0 2.5 5.0 7.5 10.	00369	0 2 4 6	0.0 2.5 5.0 7.5
В						С						
¹⁰ r =	0.82, <i>p</i> < 0.000	01										
~8-							12					
u + *						-	12			**		
o nuts						L E			**	*		
xpre						STA	9-	***	***			
						+					1	
JAK J2(n		• • •	1000			AK2		_				
, 9, ¹		•				() ²¹	6-					
2		•				60-						

log₂(norm counts +1) Viral Load • Negative • Low • Intermediate • High

6

STAT1 expression

8

10

12

0-

А



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Gene expression RNA-seq (log₂(TMM counts+1))

10000

5000

0-

MX1

MX2

ISG15

OAS1

MX1

MX2

ISG15

Calu3

NHBE

SARS-CoV-2

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

